Key points are not available for this paper at this time.
This study aimed to assess recent trends in the US use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), including incident use following newly diagnosed ASCVD.
Building similarity graph...
Analyzing shared references across papers
Loading...
Aaron A. King
Andrews University
Xi Tan
Central South University
Neil Dhopeshwarkar
TriNetX (United States)
BMJ Open Diabetes Research & Care
University of Pennsylvania
Yale University
Statistics Canada
Building similarity graph...
Analyzing shared references across papers
Loading...
King et al. (Tue,) studied this question.
synapsesocial.com/papers/68e56004e2b3180350efd445 — DOI: https://doi.org/10.1136/bmjdrc-2024-004431
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: